• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

融合基因驱动乳腺癌的内分泌治疗耐药性和转移。

fusions drive endocrine therapy resistance and metastasis in breast cancer.

作者信息

Lei Jonathan T, Gou Xuxu, Ellis Matthew J

机构信息

Interdepartmental Graduate Program in Translational Biology & Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.

出版信息

Mol Cell Oncol. 2018 Oct 9;5(6):e1526005. doi: 10.1080/23723556.2018.1526005. eCollection 2018.

DOI:10.1080/23723556.2018.1526005
PMID:30525098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6276858/
Abstract

Estrogen receptor alpha gene () fusion transcripts have been identified in breast cancer but their role in breast cancer is not completely understood. Here, we report a causal role for fusions in driving both endocrine therapy resistance and metastasis, and describe a therapeutic strategy to target fusion-induced growth.

摘要

雌激素受体α基因（）融合转录本已在乳腺癌中被鉴定出来，但其在乳腺癌中的作用尚未完全明确。在此，我们报告了融合在驱动内分泌治疗耐药性和转移方面的因果作用，并描述了一种针对融合诱导生长的治疗策略。

相似文献

1
fusions drive endocrine therapy resistance and metastasis in breast cancer.融合基因驱动乳腺癌的内分泌治疗耐药性和转移。
Mol Cell Oncol. 2018 Oct 9;5(6):e1526005. doi: 10.1080/23723556.2018.1526005. eCollection 2018.
2
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.雌激素受体阳性乳腺癌中 ESR1 基因融合的功能注释。
Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.
3
alterations and metastasis in estrogen receptor positive breast cancer.雌激素受体阳性乳腺癌的改变与转移
J Cancer Metastasis Treat. 2019;5. doi: 10.20517/2394-4722.2019.12. Epub 2019 May 4.
4
ESR1 fusions and therapeutic resistance in metastatic breast cancer.雌激素受体1（ESR1）融合与转移性乳腺癌的治疗耐药性
Front Oncol. 2023 Jan 4;12:1037531. doi: 10.3389/fonc.2022.1037531. eCollection 2022.
5
Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.对于接受新辅助芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者，突变并非内分泌抵抗的常见机制。
Front Oncol. 2020 Apr 3;10:342. doi: 10.3389/fonc.2020.00342. eCollection 2020.
6
Association of Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil.巴西雌激素受体阳性晚期乳腺癌患者的突变与内脏转移的关联
J Oncol. 2019 Aug 14;2019:1947215. doi: 10.1155/2019/1947215. eCollection 2019.
7
Increased frequency of mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.通过给予选择性雌激素受体调节剂后再给予芳香化酶抑制剂增加转移性乳腺癌的突变频率。
Oncol Lett. 2020 Aug;20(2):1231-1238. doi: 10.3892/ol.2020.11669. Epub 2020 May 22.
8
Intratumoural inflammation and endocrine resistance in breast cancer.乳腺癌中的肿瘤内炎症与内分泌抵抗
Endocr Relat Cancer. 2015 Feb;22(1):R51-67. doi: 10.1530/ERC-14-0096. Epub 2014 Nov 17.
9
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer.勘误：转移性乳腺癌中的ESR1融合与治疗耐药性。
Front Oncol. 2023 Mar 6;13:1155540. doi: 10.3389/fonc.2023.1155540. eCollection 2023.
10
Unliganded Progesterone Receptor Governs Estrogen Receptor Gene Expression by Regulating DNA Methylation in Breast Cancer Cells.未结合配体的孕激素受体通过调控乳腺癌细胞中的DNA甲基化来控制雌激素受体基因的表达。
Cancers (Basel). 2018 Oct 5;10(10):371. doi: 10.3390/cancers10100371.

引用本文的文献

1
ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.ESR1 融合导致依赖配体的致癌信号和表型在乳腺癌亚型中富集。
Endocrinology. 2024 Aug 27;165(10). doi: 10.1210/endocr/bqae111.
2
Visualization of breast cancer-related protein synthesis from the perspective of bibliometric analysis.从文献计量分析的角度看乳腺癌相关蛋白的合成。
Eur J Med Res. 2023 Oct 27;28(1):461. doi: 10.1186/s40001-023-01364-4.
3
Therapeutic resistance to anti-oestrogen therapy in breast cancer.

本文引用的文献

1
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.雌激素受体阳性乳腺癌中 ESR1 基因融合的功能注释。
Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.
2
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.ESR1 突变对转移性乳腺癌治疗的影响。
Horm Cancer. 2018 Aug;9(4):215-228. doi: 10.1007/s12672-017-0306-5. Epub 2018 May 7.
3
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.内分泌治疗耐药乳腺癌中复发性高活性 ESR1 融合蛋白。
乳腺癌对抗雌激素治疗的耐药性。
Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27.
4
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.激素受体阳性转移性乳腺癌中 ESR1 融合的临床意义和治疗策略：病例系列。
Oncologist. 2023 Feb 8;28(2):172-179. doi: 10.1093/oncolo/oyac248.
5
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.新一代选择性雌激素受体降解剂及其他用于治疗转移性激素受体阳性乳腺癌的新型内分泌疗法：当前及新出现的作用
Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113694. doi: 10.1177/17588359221113694. eCollection 2022.
6
A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.通过动态基因表达分析鉴定出一组导致乳腺癌内分泌抵抗的新基因。
Oncotarget. 2022 Apr 6;13:600-613. doi: 10.18632/oncotarget.28225. eCollection 2022.
7
Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology.中介复合物和 microRNAs 在乳腺癌发病机制中的作用。
Genes (Basel). 2022 Jan 26;13(2):234. doi: 10.3390/genes13020234.
8
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.原发性乳腺癌中 ESR1 融合基因转录本的预后和预测价值。
BMC Cancer. 2022 Feb 12;22(1):165. doi: 10.1186/s12885-022-09265-1.
9
Estrogen receptor-α signaling in post-natal mammary development and breast cancers.雌激素受体-α在产后乳腺发育和乳腺癌中的信号转导。
Cell Mol Life Sci. 2021 Aug;78(15):5681-5705. doi: 10.1007/s00018-021-03860-4. Epub 2021 Jun 22.
10
XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation.XBP1增强ESR1体细胞突变体的反式激活作用，而XBP1缺失可逆转由功能获得性Y537S ESR1突变赋予的内分泌抗性。
Heliyon. 2020 Oct 10;6(10):e05217. doi: 10.1016/j.heliyon.2020.e05217. eCollection 2020 Oct.
Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.
4
Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.短期雌激素抑制后 ER 阳性乳腺癌的基因组分析揭示了与内分泌耐药相关的改变。
Sci Transl Med. 2017 Aug 9;9(402). doi: 10.1126/scitranslmed.aai7993.
5
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.雌激素受体阳性乳腺癌侵袭性亚组中ESR1-CCDC170的复发性重排
Nat Commun. 2014 Aug 7;5:4577. doi: 10.1038/ncomms5577.
6
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.通过对乳腺癌衍生异种移植物的基因组特征分析发现的内分泌治疗耐药 ESR1 变异体。
Cell Rep. 2013 Sep 26;4(6):1116-30. doi: 10.1016/j.celrep.2013.08.022. Epub 2013 Sep 19.